However, IT administration has been shown to be generally safe, alone and in combination with other agents, with potential side effects including pyrexia, chills, pain at the injection site, and increased liver enzymes.[61a] To overcome the limitations of IT administration, several systemic STING agonists are under preclinical investigation.[61, 63, 65] However, systemic delivery of such a potent agonist raises other concerns regarding both the efficacy and safety of the applied drug regarding cytokine release syndrome, tissue toxicity, or autoimmunity due to nonspecific delivery. The gene discussed is STING1; the disease is Autoimmunity.